Novartis Claims Edge In CAR-T; Says Suicide Switch Still A Dream
This article was originally published in Scrip
Novartis AG believes the latest data for its chimeric antigen receptor T cell (CAR-T) therapy CTL019, presented at the American Society of Hematology (ASH) annual meeting, show it still has an edge over other CAR-T developers.
You may also be interested in...
Chinese biotech Innovative Cellular Therapeutics has reported promising results for its CAR-T cell immunotherapy in a small leukemia study, and the company is now planning to expand its clinical program into new indications including solid tumors, and to explore global markets.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.